Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy

Brachytherapy

Volumn 12, Issue 5, 2013, Pages 422-427

  Chen, William C ^a   Tokita, Kenneth M ^b   Ravera, John ^b   Fu, Pingfu ^c   Jiang, Ying ^c   Kaminsky, Deborah A ^a   Ponsky, Lee ^c   Ellis, Rodney J ^a,c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cancer Center of Irvine   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d Northeast Ohio Medical University   (United States)

Author keywords

Brachytherapy; Outcome assessment; Prostate cancer

Indexed keywords

LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CANCER RECURRENCE; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENCE RISK; TREATMENT RESPONSE; URINARY TRACT INJURY;

BRACHYTHERAPY; OUTCOME ASSESSMENT; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883515933     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.09.003     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
3. Beckendorf V., Guerif S., Le Prisé E., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-Year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063.
4. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
5. Kuban D.A., Levy L.B., Cheung M.R., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
6. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
7. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192-iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533.
8. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
9. Roach M., Marquez C., You H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994, 28:33-37.
10. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
11. Ko E.C., Stone N.N., Stock R.G. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 2012, 83:600-607.
12. The Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, version 4.0. Available at: Accessed August 30,2012. http://ctep.cancer.gov/protocoldevelopment/.
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
14. Cox D.R. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972, 34:187-197.
15. National Comprehensive Cancer Center (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer, version 4.2011. Available at: Accessed January 10,2011. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
16. Alicikus Z.A., Yamada Y., Zhang Z., et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437.
17. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
18. Jabbari S., Weinberg V.K., Kaprealian T., et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2011, 82:228-234.
19. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:316-327.
20. Kim Y., Hsu I.J., Lessard E., et al. Class Solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol 2008, 88:148-155.
21. Kazi A., Godwin G., Simpson J., et al. MRI-guided HDR brachytherapy boost to the dominate intraprostatic lesion in high risk localized prostate cancer. BMC Cancer 2010, 10:472.
22. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
23. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-Year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
24. A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer, Radiation Therapy OncologyStudy Group. Available at: Accessed April 15, 2012. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815.
25. Katz A.J., Santoro M., Ashley R., et al. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010, 9:575-582.
26. King C.R., Brooks J.D., Gill H., et al. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048.
27. Ellis R.J., Kaminsky D.A., Zhou E.H., et al. Ten-year outcomes: The clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:29-34.
28. Joseph T., McKenna D.A., Westphalen A.C., et al. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009, 73:665-671.
29. Fradet V., Kurhanewicz J., Cowan J.E., et al. Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010, 256:176-183.
30. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline. J Nucl Med 2011, 52:81-89.